Rafferty Asset Management LLC Has $14.22 Million Position in DexCom, Inc. $DXCM

Key Points

• Rafferty Asset Management LLC has increased its holdings in DexCom, Inc. to $14.22 million, owning 208,239 shares after acquiring an additional 3,380 shares in the first quarter.
• In the past quarter, several large institutions, including Golden State Wealth Management LLC and Zions Bancorporation, have significantly increased their stakes in DexCom, showcasing strong institutional interest with 97.75% of the stock owned by institutional investors.
• DexCom reported earnings of $0.48 per share for the last quarter, exceeding the consensus estimate, alongside a revenue growth of 15.2% year-over-year, totaling $1.16 billion.

Rafferty Asset Management LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 208,239 shares of the medical device company's stock after purchasing an additional 3,380 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.05% of DexCom worth $14,221,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of DXCM. Golden State Wealth Management LLC boosted its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom during the 1st quarter worth approximately $27,000. Optiver Holding B.V. bought a new position in DexCom during the 4th quarter worth approximately $33,000. Heck Capital Advisors LLC bought a new position in DexCom during the 4th quarter worth approximately $38,000. Finally, Alpine Bank Wealth Management bought a new position in DexCom during the 1st quarter worth approximately $40,000. Institutional investors own 97.75% of the company's stock.

Insider Activity

In related news, EVP Sadie Stern sold 1,466 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares in the company, valued at approximately $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,722 shares of company stock valued at $1,306,131 in the last ninety days. Corporate insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DXCM shares. Citigroup reissued a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Piper Sandler lifted their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. The Goldman Sachs Group started coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Finally, UBS Group lifted their price objective on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.89.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM traded up $0.26 during midday trading on Friday, reaching $75.34. The company's stock had a trading volume of 2,921,932 shares, compared to its average volume of 4,186,415. The stock has a market capitalization of $29.54 billion, a price-to-earnings ratio of 52.32, a PEG ratio of 1.58 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The stock has a 50 day simple moving average of $82.25 and a 200-day simple moving average of $79.44. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.